Bridge is a demonstration. Part D is the benefit.

Different legal animals

Part D (or the Part D piece of an MA-PD) is the ongoing Medicare drug benefit. The GLP-1 Bridge is a CMS demonstration from 1 July 2026 to 31 December 2027 with a flat $50 month for three named products (Wegovy pen and pill, Foundayo, Zepbound KwikPen).

VitalHound is not a plan and not CMS. It will not move you between these animals. It will tell you which animal the written indication belongs to.

Indication is the switch

Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and MASH: Part D first. CMS does not want those prescriptions steered onto Bridge.

Weight-management demonstration: Bridge if the other eligibility screens match. Part D often excludes obesity GLP-1s, which is why the demonstration exists.

Money behaves differently

Part D: deductible, copay or coinsurance, Extra Help if eligible, TrOOP credit on qualifying spend. Bridge: $50, no Extra Help, no deductible credit, no TrOOP.

A person already filling a 2026 Part D GLP-1 is generally ineligible for Bridge. That is a fence, not a suggestion.

How denials should route

Part D denial on a coverable indication: appeal or exception, then cash if the exception dies. Bridge denial on a demonstration case: cash or a different listed drug, not a commercial savings card.

Telehealth bundles near $449 are not a third Medicare benefit.

2027–2028

Bridge has a cliff. Part D does not vanish. Autumn 2027 open enrollment is when the formulary must replace the $50. Shop as if the demonstration will actually end.